TOPIRAMATE | A205976 | PH HEALTH LTD
| Case | Court | Filed | Status | Judge |
|---|---|---|---|---|
SUPERNUS PHARMACEUTICALS, INC. v. PAR PHARMACEUTICAL COMPANIES, INC. et al 4 patentsANDA 205976Topiramate | D.N.J. | 2015-01-16 | Terminated 2015-10-16 | — |
Source: PACER. NOS 835 (Patent - Abbreviated New Drug Application).
Highest NADAC/Unit
$23.21
per ea
Lowest NADAC/Unit
$3.83
per ea
Brand NDCs
0
Generic NDCs
8
| NDC Description | NADAC/Unit | Unit | Type | Generic NADAC | Effective |
|---|---|---|---|---|---|
| 10370036801TOPIRAMATE ER 200 MG CAPSULE | $23.21 | EA | Generic | — | 2026-06-17 |
| 10370036811TOPIRAMATE ER 200 MG CAPSULE | $23.21 | EA | Generic | — | 2026-06-17 |
| 10370036701TOPIRAMATE ER 100 MG CAPSULE | $10.76 | EA | Generic | — | 2026-06-17 |
| 10370036711TOPIRAMATE ER 100 MG CAPSULE | $10.76 | EA | Generic | — | 2026-06-17 |
| 10370036601TOPIRAMATE ER 50 MG CAPSULE | $6.27 | EA | Generic | — | 2026-06-17 |
| 10370036611TOPIRAMATE ER 50 MG CAPSULE | $6.27 | EA | Generic | — | 2026-06-17 |
| 10370036501TOPIRAMATE ER 25 MG CAPSULE | $3.83 | EA | Generic | — | 2026-06-17 |
| 10370036511TOPIRAMATE ER 25 MG CAPSULE | $3.83 | EA | Generic | — | 2026-06-17 |
Source: NADAC (data.medicaid.gov). Prices reflect national average acquisition costs for retail community pharmacies.
No patent or exclusivity listings for this strength.